NSAID GASTROPATHIES: PREDICTING THEIR COURSE AND OUTCOMES

DOI: https://doi.org/10.29296/25877305-2018-05-04
Download full text PDF
Issue: 
5
Year: 
2018

A. Khudarova; Professor M. Osadchuk, MD I.M. Sechenov First Moscow State Medical University (Sechenov University)

The problem of NSAID gastropathy is becoming a greater sociomedical importance due to the wide and frequently uncontrolled use of nonsteroidal anti-inflammatory drugs and to the risk of serious gastrointestinal complications.

Keywords: 
gastroenterology
nonsteroidal anti-inflammatory drugs (NSAID)
NSAID gastropathy
proton pump inhibitors



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Barskova V.G. Chto nam daet izuchenie statistiki prodazh nesteroidnyh protivovospalitel'nyh preparatov v Rossijskoj Federatsii? // Sovremennaja revmatologija. – 2011; 5 (3): 68–73.
  2. Vpasjuk V.B. Lechenie oslozhnennoj jazvennoj bolezni dvenadtsatiperstnoj kishki: sovremennye tendentsii v terapevticheskoj i hirurgicheskoj praktike // Sovremennaja meditsina. – 2010. URL: http://www.medblog.com.ua/articles/diseases/2371
  3. Zolotarev V.A. Nozdrachev A.D. Kapsaitsin-chuvstvitel'nye afferenty bluzhdajuschego nerva // Ross. fiziol. zhurn. – 2001; 87 (2): 182–204.
  4. Ivashkin V.T., Sheptulin A.A., Branskaja E.K. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniju erozivno-jazvennyh porazhenij zheludka i dvenadtsatiperstnoj kishki, vyzvannyh nesteroidnymi protivovospalitel'nymi preparatami. Klinicheskie rekomendatsii / M., 2014.
  5. Karateev A.E. i dr. Klinicheskie rekomendatsii «Ratsional'noe primenenie nesteroidnyh protivovospalitel'nyh preparatov (NPVP) v klinicheskoj praktike» // Sovremennaja revmatologija. – 2015; 9 (1): 4–23.
  6. Karateev A.E., Uspenskij Ju.P., Pahomova I.G. i dr. Kombinirovannoe lechenie jazv zheludka, indutsirovannyh nesteroidnymi protivovospalitel'nymi preparatami. Rezul'taty 4-nedel'nogo otkrytogo kontroliruemogo issledovanija po otsenke effektivnosti kombinatsii ingibitora protonnoj pompy i vismuta trikalija ditsitrata // Ter. arh. – 2009; 81 (6): 62–6.
  7. Nasonov E.L., Karateev A.E. Primenenie nesteroidnyh protivovospalitel'nyh preparatov. Klinicheskie rekomendatsii // RMZh. – 2006; 25: 1769.
  8. Nasonov E.L., Ivashkin V.T., Jahno N.N. i dr. Ratsional'noe primenenie nesteroidnyh protivovospalitel'nyh preparatov po rezul'tatam soveschanija gruppy ekspertov // Nauchno-prakt. revmatol. – 2017; 55 (4): 452–6.
  9. Pahomova I.G. Novye vozmozhnosti v minimizatsii riska NPVP-indutsirovannyh gastropatij // RMZh. – 2014; 10: 772.
  10. Strachunskij L.S., Kozlov S.N. Nesteroidnye protivovospalitel'nye sredstva. Metodicheskoe posobie, 2017.
  11. Sheptulin A.A., Lapina T.L., Kajbysheva V.O. Novoe v izuchenii infektsii Helicobacter pylori i osnovnye polozhenija Soglasitel'nogo soveschanija Maastriht-V (2016) // Ros. zhurn. gastroenterol, gepatol. i koloproktol. – 2017; 27 (1): 35–43.
  12. Carli D., Pires R., Rohde S. et al. Peptic ulcer frequency differences related to N. pylori or aines // Arq. Gastroenterol. – 2015; 52 (1): 46–9.
  13. De Pretis G., Tasini E. Tollerabilita gastrica dell’antiinfiammatorio Amtolmetina Guacil: meta-analisi dei trials terapeutici / Med. Ther, 2002.
  14. Hawkey C., Wight N. NSAIDs and gastrointestinal complications / London: Life Science Communications, 2001; p. 1–56.
  15. Harry Hua-Xiang Xia et al. Reduction of Peptic Ulcer Disease and Helicobacter pylori Infection but Increase of Reflux Esophagitis in Western Sydney Between 1990 and 1998 // Dig. Dis. Sci. –2001; 46 (Issue 12): 2716–23.
  16. Ramakrishnan K., Salinas R. Peptic Ulcer Disease // Oklahoma Am. Fam. Physician. – 2007; 76 (7): 1005–12.
  17. Lanas A., Garcia-Rodriguez L., Arroyo M. et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations // Gut. – 2006; 55: 1731–8.
  18. Lanas A., Hunt R.. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies // Ann. Med. – 2006; 38: 415–28.
  19. Lain L. Approaches to nonsteroidal anti-inflammatory drugs in the high-risk patients // Gastroenterology. – 2001; 2: 594–606.
  20. Lanas A., Garcia-Rodriguez L., Arroyo M. et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants // Clin. Gastroenterol. Hepatol. – 2015; 13 (5): 906–12.
  21. Lanas A., Tornero J., Zamorano J.. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study // Ann. Rheum. Dis. – 2010; 69 (8): 1453–8.
  22. Lué A., Lanas A. Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits // World J. Gastroenterol. – 2016; 22 (48): 10477–81.
  23. Lyseng-Williamson K., Foster R. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis // Pharmacoeconomics. – 2004; 22 (2): 107–32.
  24. Malfertheiner P., Megraud F., O'Morain C. et al. European Helicobacter Study Group Management of Helicobacter pylori infection--the Maastricht IV // J. Florence Consensus Report. Gut. – 2012; 61 (5): 646–64.
  25. Mearin F., Ponce J. Potent acid inhibition: summary of the evidence and clinical application // Drugs. – 2005; 65 (Suppl. 1): 113–26.
  26. Montrone F., Santandrea S., Caruso I. et al. Amtolmetin guacyl versus piroxicam in patients with osteoarthritis // J. Int. Med. Res. – 2000; 28 (2): 91–100.
  27. Rostom A., Moayyedi P., Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks // Aliment. Pharmacol. Ther. – 2009; 29: 481–96.
  28. Shaheen N., Hansen R., Morgan D. et al. The burden of gastrointestinal and liver diseases // Am. J. Gastroenterol. – 2006; 101: 2128–38.
  29. Sostres C., Jerusalen C., Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights // World J. Gastroenterol. – 2014; 20 (28): 9439–50.
  30. Straube S., Tramèr M., Moore R. et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use // BMC Gastroenterol. – 2009; 9: 41.
  31. Tannenbaum H., Bombardier C., Davis P. et al. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference // J. Rheumatol. – 2006; 33: 140–57.
  32. Yakabi K., Kamiichi H., Ohno S. et al. Arteriosclerosis and gastroduodenal ulcer // Nippon Rinsho. – 2004; 62 (3): 525–31.